Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In
  • Become a Member
  • MB Vision
  • Members
    • Become a Member
      • Types & Rates
    • Benefits
      • Savings and Rewards
    • Member News
    • Member Events
    • Career Center
    • Directory
    • Pay Company Dues
    • FAQs
  • Events
    • Upcoming
    • Types of Events
    • Sponsorship Opportunities
    • The State of Possible Conference
    • Align Summit
    • Member Events
  • Innovation
    • About
    • Drive
      • Application
      • Alumni
      • Partners – MassBio
      • Partners – SCbio
      • Get Involved
      • FAQs
    • CEO & Founder Link
    • Align Summit
    • Partnering
    • Sponsorship Opportunities
  • Savings
    • MassBioEdge
  • Conference Center
    • About MassBioHub
    • Packages & Special Offers
    • Venue Specifications
    • Reserve Today
  • Policy & Advocacy
    • Policy & Advocacy Efforts
    • Diversity, Equity, and Inclusion
      • DEI Report
      • Resource Center
      • Open Letter 2.0
      • Bioversity
    • Economic Development
      • BioReady® Communities
    • Workforce Development
      • Bioversity
    • Vision 2030
    • This is the place.
    • Industry Reports
      • Federal Actions Impact Report
      • Industry Snapshot
      • Biopharma Funding Report
      • DEI Report
      • MA Life Sciences Workforce
  • About
    • About MassBio
    • News & Thought Leadership
    • MB Vision
    • The Studio at Kendall Square
    • Sponsorship Opportunities
    • Staff
    • Board
    • Contact Us
  • Sign In
  • Become a Member
  • MB Vision
Open search form

Member Directory

Click to Open Main Menu

Paratek Pharmaceuticals, Inc.

Life Sciences | Drug Development
Boston, MA 617-807-6600 Website @ParatekPharma LinkedIn

Overview

Paratek Pharmaceuticals, Inc., is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company has used its expertise in biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the minocycline core structure. Its United States, or U.S., Food and Drug Administration, or FDA, approved commercial product, NUZYRA® (omadacycline) is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, and acute skin and skin structure infections, or ABSSSI, caused by susceptible pathogens. SEYSARA® (sarecycline) is an FDA-approved product with respect to which that Company has exclusively licensed in the U.S. and the People’s Republic of China, Hong Kong and Macau, or the greater China region, certain rights to Almirall, LLC, or Almirall. SEYSARA is currently being marketed by Almirall in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. With respect to the Company’s technology as it relates to sarecycline, it retains development and commercialization rights in all countries other than the U.S. and the greater China region, and in February 2020, the Company exclusively licensed from Almirall certain technology owned or in-licensed by Almirall or its affiliates that is necessary or useful to develop or commercialize sarecycline outside of the U.S.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • News & Thought Leadership
  • Pay Company Dues
  • Join Today
  • Contact
  • Privacy Policy
  • © 2025 All Rights Reserved